Literature DB >> 10435802

Cancer of the tonsil: the results of ipsilateral radiation treatment.

S M Jackson1, J H Hay, A D Flores, L Weir, F L Wong, C Schwindt, B Baerg.   

Abstract

BACKGROUND AND
PURPOSE: The use of ipsilateral irradiation techniques to treat patients with carcinoma of the tonsil reduces the acute radiation reaction in the contralateral pharynx and late damage to the contralateral salivary tissue. However, this may also spare microscopic disease in apparently uninvolved contralateral lymph nodes. The purpose of this study was to analyse the survival and recurrence rates and sites of recurrance in a group of patients with carcinoma of the tonsil treated with ipsilateral techniques.
MATERIALS AND METHODS: Between 1975 and 1993, 271 patients with invasive squamous cell cancer of the tonsil were referred to the Vancouver Cancer Centre (VCC). One hundred and seventy-eight received ipsilateral radiation treatment. Three received surgery only, six post-operative radiation, 12 supportive treatment only and 72 bilateral radiation treatment. In the absence of bilateral neck nodes and extensive lymphodenopathy, field sizes were generally kept small to include the primary tumour and the first echelon of nodes. The most common dose was 60 Gy in 25 daily fractions in 5 weeks (2.4 Gy per day). RESULTS AND DISCUSSION: The disease specific survival for all patients treated by radical radiation treatment was 61% at 5 years. For the 178 patients who received ipsilateral radiation treatment the overall primary tumour control rate by ipsilateral radiation treatment alone was 75% and for T1 and T2 tumours 84%. Eight (7.5%) of 101 of these patients with N0 nodes at presentation and without prior failure at the primary site, developed nodal recurrence (four within the initially radiated high dose volume). Two developed contralateral nodes, and two developed field edge nodal recurrence, one cured by surgery. In 54 patients with N1 disease, five developed nodal recurrence, two within field, two contralateral, one of whom was cured by surgery, and one at field edge. In 23 patients with N2a, N2b or N3 disease node control was achieved from radiation treatment in 11 and two more were cured by surgery. All nodal failures were within the radiated volume. Overall, 10 of the 25 patients with nodal failure were cured by subsequent surgery.
CONCLUSIONS: Ipsilateral treatment of patients with carcinoma of the tonsil gives survival results that are at least as good as those reported with bilateral treatment with fewer side effects and a very low risk of failure in the contralateral neck.

Entities:  

Mesh:

Year:  1999        PMID: 10435802     DOI: 10.1016/s0167-8140(99)00051-1

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  17 in total

1.  Unilateral neck therapy in the human papillomavirus ERA: accepted regional spread patterns.

Authors:  Thomas J Galloway; Miriam N Lango; Barbara Burtness; Ranee Mehra; Karen Ruth; John A Ridge
Journal:  Head Neck       Date:  2012-02-02       Impact factor: 3.147

2.  Radiotherapy alone or combined with chemotherapy as definitive treatment for squamous cell carcinoma of the tonsil.

Authors:  William R Kennedy; Michael P Herman; Rohan L Deraniyagala; Robert J Amdur; John W Werning; Peter Dziegielewski; Jessica Kirwan; Christopher G Morris; William M Mendenhall
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-08       Impact factor: 2.503

3.  Squamous cell carcinoma of the tonsillar remnant--clinical presentation and oncological outcome.

Authors:  Christopher J Skilbeck; Jean-Pierre Jeannon; Mary O'Connell; Peter R Morgan; Ricard Simo
Journal:  Head Neck Oncol       Date:  2011-01-19

4.  Unilateral Radiation Therapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papillomavirus, Positron-Emission Tomography, and Intensity Modulated Radiation Therapy.

Authors:  Nicolette Taku; Gregory Chronowski; G Brandon Gunn; William H Morrison; Neil D Gross; Amy C Moreno; Renata Ferrarotto; Steven J Frank; C David Fuller; Ryan P Goepfert; Jack Phan; Stephen Y Lai; Jay P Reddy; David I Rosenthal; Adam S Garden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2022-05-02       Impact factor: 8.013

5.  Recurrent oropharyngeal cancer after organ preserving treatment: pattern of failure and survival.

Authors:  M de Ridder; Z A R Gouw; J J Sonke; A Navran; B Jasperse; J Heukelom; M E T Tesselaar; W M C Klop; M W M van den Brekel; Abrahim Al-Mamgani
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-09       Impact factor: 2.503

6.  Ipsilateral radiotherapy for squamous cell carcinoma of the tonsil.

Authors:  William R Kennedy; Michael P Herman; Rohan L Deraniyagala; Robert J Amdur; John W Werning; Peter T Dziegielewski; Christopher G Morris; William M Mendenhall
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-07-30       Impact factor: 2.503

7.  Low risk of contralateral lymph node recurrence in lateralized head and neck carcinoma after postoperative ipsilateral radiotherapy.

Authors:  Mirja M Wirtz; Susanne Temming; Martin Kocher; Sabine Kunze; Robert Semrau
Journal:  Strahlenther Onkol       Date:  2019-12-12       Impact factor: 3.621

8.  Results of transoral laser microsurgery in 102 patients with squamous cell carcinoma of the tonsil.

Authors:  Martin Canis; Alexios Martin; Martina Kron; Alexandra Konstantinou; Friedrich Ihler; Hendrik A Wolff; Christoph Matthias; Wolfgang Steiner
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-12-29       Impact factor: 2.503

9.  Ipsilateral irradiation for well lateralized carcinomas of the oral cavity and oropharynx: results on tumor control and xerostomia.

Authors:  Laura Cerezo; Margarita Martín; Mario López; Alicia Marín; Alberto Gómez
Journal:  Radiat Oncol       Date:  2009-09-01       Impact factor: 3.481

10.  Evaluation of radiotherapy techniques for radical treatment of lateralised oropharyngeal cancers : Dosimetry and NTCP.

Authors:  D McQuaid; A Dunlop; S Nill; C Franzese; C M Nutting; K J Harrington; K L Newbold; S A Bhide
Journal:  Strahlenther Onkol       Date:  2016-06-13       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.